Study to evaluate the safety and efficacy of formoterol in a daily dose of 18 µg (9 µg twice daily) in Japanese chronic obstructive pulmonary disease (COPD) patients

Exclusion Criteria

• - A history and/or current clinical diagnosis of asthma and atopic diseases such as Allergic rhinitis
• - Patients who have experienced COPD exacerbation requiring at least one of the following treatment, hospitalisation and/or a course of systemic steroid within 4 weeks prior to the study start.
• - Significant or unstable ischaemic heart disease, arrhythmia, cardiomyopathy, heart failure, uncontrolled hypertension as defined by the investigator, or any other relevant cardiovascular disorder as judged by the investigator